Interview with Maurizio De Cicco, General Manager, Roche Italy
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
Address: Viale Shakespeare, 47 – 00144 Rome,Italy
Tel: +39.06.592.64.43
Sigma-tau is a leading Italian pharmaceutical group, established in 1957 that counts today 2432 employees worldwide amongst whom about 400 researchers. It reached a turnover of 605 million euros in 2008.
The headquarters of the group are in Pomezia, and Sermoneta – in the province of Latina- has active installations Biosint for the production of pharmaceutical raw materials, of L-carnitine and its derivatives.
In 2001 was established BiofuturaPharma, based in Milan, that aims to develop pharmaceuticals for the treatment of diseases of the central nervous system and respiratory system. Recently the business has extended to the development and commercialization of products derived from the biological system of carnitine.
Sigma-Tau works through the National Organization for Rare Disorders (NORD) to provide patient assistance programs to help ensure that patients who are underinsured or otherwise financially limited receive their products at little or no cost.
Always investing in research, 16% of turnover in 2008, Sigma-tau aims to continue its development by:
* Increasing commitment to research in biopharma
* Continuous technological upgrading of production systems
* High-quality products
Roche Italy is one of the companies which went through the most significant re-organization process in the country in the past three years- with important changes in both its marketing…
When you were appointed General Director of the Agenzia Italiana del Farmaco (AIFA) in 2007, the dedicated Investigation Commission highlighted the need for an in-depth reorganization of the Agency in…
When you became President of Sankyo Pharma Italy in 2003 one of your objectives was to maximize sales of the existing portfolio- and the company’s sales have impressively tripled in…
Intermediate distribution plays a crucial role in establishing bridges between industrial production and final delivery to patients- and in Italy, this function is executed with highly contained costs and commercial…
You have led a successful career within the Solvay Group in various European countries. Looking back at all these international assignments, including you current function of regional Director South Europe,…
Biotechnologies have a significant role to play bringing Italy towards a more knowledge-based economy. What is the economic contribution of the sector today? According to the last Blossom Associati-Assobiotec report…
After long experience in the pharmaceutical industry, working in both multinational and local laboratories, you took the reins of the already well-established Italian subsidiary of Ferring a few months ago.…
Dr Fazi, you co-founded Eurogroup Consulting (EGC) in Italy in 2007 and are now leading a well established reality, renowned for the new model of governance it has designed. Could…
Following the successful result of the “Piano Sanitario Nazionale” 2005 – 2008, could you introduce to ours readers the key priorities and main health policies to be implemented by 2009…
Following 20 years of a comprehensive experience in diverse fields of the pharmaceutical industry, you entered Baxter in 2000. At the time, the Italian affiliate was already a well established…
Despite Italy being one of the most important pharmaceutical markets not only in Europe but also in the World, the industry remained quite stable for the last two years and…
Grunenthal-Formenti relies on Formenti’s 60 years experience in Italy and is the result of the merger of both the German and Italian entities in 96. How would you describe the…
See our Cookie Privacy Policy Here